Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Guggenheim Upgrades Guardant Health to Buy, Announces $36 Price Target

Author: Benzinga Newsdesk | June 28, 2024 08:00am
Guggenheim analyst Subbu Nambi upgrades Guardant Health (NASDAQ:GH) from Neutral to Buy and announces $36 price target.

Posted In: GH